SPOTLIGHT: FDA greenlights Pozen Phase III

The FDA has given Pozen a green light for its Phase III trial of PN 2000 for arthritis. The Chapel Hill, NC-based drug developer says it should begin the pivotal trial in the next few months. Pozen was dealt a significant blow last summer when the FDA rejected its MT 100 for migraines. Report